Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases

for the Alzheimer Precision Medicine Initiative (APMI)

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

The discovery, development, and validation of novel candidate biomarkers in Alzheimer’s disease (AD) and other neurodegenerative diseases (NDs) are increasingly gaining momentum. As a result, evolving diagnostic research criteria of NDs are beginning to integrate biofluid and neuroimaging indicators of pathophysiological mechanisms. More than 10% of people aged over 65 suffer from NDs. There is an urgent need for a refined two-stage diagnostic model to first initiate an early, sensitive, and noninvasive process in primary care settings. Individuals that meet detection criteria will then be channeled to more specific, costly (positron-emission tomography), and invasive (cerebrospinal fluid) assessment methods for confirmatory biological characterization and diagnosis. A reliable and sensitive blood test for AD and other NDs is not yet established; however, it would provide the golden screening gate for an efficient primary care management. A limitation to the development of a large-scale blood-screening biomarker-based test is the traditional application of clinically descriptive criteria for the categorization of single late-stage ND constructs. These are genetically and biologically heterogeneous, reflected in multiple pathophysiological mechanisms and subsequent pathologies throughout a dimensional continuum. Evidence suggests that a shared, “open-source” integrated multilevel categorization of NDs that clusters individuals based on descriptive clinical phenotypes and pathophysiological biomarker signatures will provide the next incremental step toward an improved diagnostic process of NDs. This intermediate objective toward unbiased biomarker-guided early detection of individuals at risk for NDs is currently carried out by the international pilot Alzheimer Precision Medicine Initiative Cohort Program (APMI-CP).

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages139-155
Number of pages17
DOIs
StatePublished - 1 Jan 2018

Publication series

NameMethods in Molecular Biology
Volume1750
ISSN (Print)1064-3745

Fingerprint

Neurodegenerative Diseases
Biomarkers
Primary Health Care
Alzheimer Disease
Precision Medicine
Hematologic Tests
Neuroimaging
Positron-Emission Tomography
Cerebrospinal Fluid
Pathology
Phenotype
Research

Keywords

  • Alzheimer precision medicine initiative
  • Alzheimer’s disease
  • Biomarkers
  • Blood
  • Neurodegenerative diseases
  • Pathophysiology
  • Precision medicine
  • Screening
  • Systems biology
  • Systems neurophysiology

Cite this

for the Alzheimer Precision Medicine Initiative (APMI) (2018). Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. In Methods in Molecular Biology (pp. 139-155). (Methods in Molecular Biology; Vol. 1750). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-7704-8_9
for the Alzheimer Precision Medicine Initiative (APMI). / Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. Methods in Molecular Biology. Humana Press Inc., 2018. pp. 139-155 (Methods in Molecular Biology).
@inbook{40540a8860c4452eaab49f91ad097ed2,
title = "Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases",
abstract = "The discovery, development, and validation of novel candidate biomarkers in Alzheimer’s disease (AD) and other neurodegenerative diseases (NDs) are increasingly gaining momentum. As a result, evolving diagnostic research criteria of NDs are beginning to integrate biofluid and neuroimaging indicators of pathophysiological mechanisms. More than 10{\%} of people aged over 65 suffer from NDs. There is an urgent need for a refined two-stage diagnostic model to first initiate an early, sensitive, and noninvasive process in primary care settings. Individuals that meet detection criteria will then be channeled to more specific, costly (positron-emission tomography), and invasive (cerebrospinal fluid) assessment methods for confirmatory biological characterization and diagnosis. A reliable and sensitive blood test for AD and other NDs is not yet established; however, it would provide the golden screening gate for an efficient primary care management. A limitation to the development of a large-scale blood-screening biomarker-based test is the traditional application of clinically descriptive criteria for the categorization of single late-stage ND constructs. These are genetically and biologically heterogeneous, reflected in multiple pathophysiological mechanisms and subsequent pathologies throughout a dimensional continuum. Evidence suggests that a shared, “open-source” integrated multilevel categorization of NDs that clusters individuals based on descriptive clinical phenotypes and pathophysiological biomarker signatures will provide the next incremental step toward an improved diagnostic process of NDs. This intermediate objective toward unbiased biomarker-guided early detection of individuals at risk for NDs is currently carried out by the international pilot Alzheimer Precision Medicine Initiative Cohort Program (APMI-CP).",
keywords = "Alzheimer precision medicine initiative, Alzheimer’s disease, Biomarkers, Blood, Neurodegenerative diseases, Pathophysiology, Precision medicine, Screening, Systems biology, Systems neurophysiology",
author = "{for the Alzheimer Precision Medicine Initiative (APMI)} and Filippo Baldacci and Simone Lista and Sidney O'Bryant and Roberto Ceravolo and Nicola Toschi and Harald Hampel",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-7704-8_9",
language = "English",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "139--155",
booktitle = "Methods in Molecular Biology",

}

for the Alzheimer Precision Medicine Initiative (APMI) 2018, Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1750, Humana Press Inc., pp. 139-155. https://doi.org/10.1007/978-1-4939-7704-8_9

Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. / for the Alzheimer Precision Medicine Initiative (APMI).

Methods in Molecular Biology. Humana Press Inc., 2018. p. 139-155 (Methods in Molecular Biology; Vol. 1750).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases

AU - for the Alzheimer Precision Medicine Initiative (APMI)

AU - Baldacci, Filippo

AU - Lista, Simone

AU - O'Bryant, Sidney

AU - Ceravolo, Roberto

AU - Toschi, Nicola

AU - Hampel, Harald

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The discovery, development, and validation of novel candidate biomarkers in Alzheimer’s disease (AD) and other neurodegenerative diseases (NDs) are increasingly gaining momentum. As a result, evolving diagnostic research criteria of NDs are beginning to integrate biofluid and neuroimaging indicators of pathophysiological mechanisms. More than 10% of people aged over 65 suffer from NDs. There is an urgent need for a refined two-stage diagnostic model to first initiate an early, sensitive, and noninvasive process in primary care settings. Individuals that meet detection criteria will then be channeled to more specific, costly (positron-emission tomography), and invasive (cerebrospinal fluid) assessment methods for confirmatory biological characterization and diagnosis. A reliable and sensitive blood test for AD and other NDs is not yet established; however, it would provide the golden screening gate for an efficient primary care management. A limitation to the development of a large-scale blood-screening biomarker-based test is the traditional application of clinically descriptive criteria for the categorization of single late-stage ND constructs. These are genetically and biologically heterogeneous, reflected in multiple pathophysiological mechanisms and subsequent pathologies throughout a dimensional continuum. Evidence suggests that a shared, “open-source” integrated multilevel categorization of NDs that clusters individuals based on descriptive clinical phenotypes and pathophysiological biomarker signatures will provide the next incremental step toward an improved diagnostic process of NDs. This intermediate objective toward unbiased biomarker-guided early detection of individuals at risk for NDs is currently carried out by the international pilot Alzheimer Precision Medicine Initiative Cohort Program (APMI-CP).

AB - The discovery, development, and validation of novel candidate biomarkers in Alzheimer’s disease (AD) and other neurodegenerative diseases (NDs) are increasingly gaining momentum. As a result, evolving diagnostic research criteria of NDs are beginning to integrate biofluid and neuroimaging indicators of pathophysiological mechanisms. More than 10% of people aged over 65 suffer from NDs. There is an urgent need for a refined two-stage diagnostic model to first initiate an early, sensitive, and noninvasive process in primary care settings. Individuals that meet detection criteria will then be channeled to more specific, costly (positron-emission tomography), and invasive (cerebrospinal fluid) assessment methods for confirmatory biological characterization and diagnosis. A reliable and sensitive blood test for AD and other NDs is not yet established; however, it would provide the golden screening gate for an efficient primary care management. A limitation to the development of a large-scale blood-screening biomarker-based test is the traditional application of clinically descriptive criteria for the categorization of single late-stage ND constructs. These are genetically and biologically heterogeneous, reflected in multiple pathophysiological mechanisms and subsequent pathologies throughout a dimensional continuum. Evidence suggests that a shared, “open-source” integrated multilevel categorization of NDs that clusters individuals based on descriptive clinical phenotypes and pathophysiological biomarker signatures will provide the next incremental step toward an improved diagnostic process of NDs. This intermediate objective toward unbiased biomarker-guided early detection of individuals at risk for NDs is currently carried out by the international pilot Alzheimer Precision Medicine Initiative Cohort Program (APMI-CP).

KW - Alzheimer precision medicine initiative

KW - Alzheimer’s disease

KW - Biomarkers

KW - Blood

KW - Neurodegenerative diseases

KW - Pathophysiology

KW - Precision medicine

KW - Screening

KW - Systems biology

KW - Systems neurophysiology

UR - http://www.scopus.com/inward/record.url?scp=85043456563&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7704-8_9

DO - 10.1007/978-1-4939-7704-8_9

M3 - Chapter

C2 - 29512070

AN - SCOPUS:85043456563

T3 - Methods in Molecular Biology

SP - 139

EP - 155

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -

for the Alzheimer Precision Medicine Initiative (APMI). Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. In Methods in Molecular Biology. Humana Press Inc. 2018. p. 139-155. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-7704-8_9